申请人:Ciba-Geigy Corporation
公开号:US05639768A1
公开(公告)日:1997-06-17
The invention relates to the compounds of formula (I) wherein the C(.dbd.NH)--NHR.sub.3 group may be in tautomeric or isomeric form, and pharmaceutically acceptable salts thereof, in which: R.sub.1 is amino which is mono- or disubstituted by a substituent selected from an aliphatic hydrocarbon radical, an araliphatic hydrocarbon radical, an aromatic radical, and a cycloaliphatic hydrocarbon radical or is amino which is disubstituted by a divalent aliphatic hydrocarbon radical or a said radical interrupted by oxygen; R.sub.2 is hydroxy which is etherified by an aliphatic alcohol which is substituted by carboxy, by esterified carboxy or by amidated carboxy; R.sub.3 is hydrogen or an acyl radical which is derived from an organic carbonic acid, an organic carboxylic acid, a sulfonic acid, or a carbamic acid; X.sub.1 and X.sub.3, independently of one another, are oxygen (--O--) or sulphur (--S--); and X.sub.2 is a divalent aliphatic hydrocarbon radical which may be interrupted by an aromatic radical. The compounds are useful as selective LTB.sub.4 receptor antagonists in the treatment of conditions or syndromes in mammals which are responsive to LTB.sub.4 receptor antagonism.
该发明涉及具有以下式(I)的化合物,其中C(.dbd.NH)--NHR.sub.3基团可以是互变异构体或同分异构体形式,并且其药学上可接受的盐,其中:R.sub.1是氨基,可以是由来自脂肪烃基、芳基烃基、芳基或环脂烃基的取代基单取代或双取代的氨基,也可以是由双价脂肪烃基或被氧中断的所述基团取代的氨基;R.sub.2是被脂肪醇醚化的羟基,该脂肪醇被羧基、酯化羧基或酰胺化羧基取代;R.sub.3是氢或由有机碳酸、有机羧酸、磺酸或碳酸衍生的酰基基团;X.sub.1和X.sub.3,彼此独立地,是氧(--O--)或硫(--S--);而X.sub.2是可以由芳基中断的双价脂肪烃基。这些化合物在治疗对LTB.sub.4受体拮抗剂敏感的哺乳动物的病症或综合症中作为选择性LTB.sub.4受体拮抗剂是有用的。